GLP-1 safety

Can Ozempic, Wegovy, or Mounjaro Affect Eyesight?

Vision symptoms on GLP-1 treatment need context. Temporary blurred vision, diabetic retinopathy, and rare optic nerve events are different problems with different risk groups.

Élan Clinic · Educational article · Published June 13, 2026 · Reviewed June 13, 2026

Patients sometimes ask whether Ozempic, Wegovy, or Mounjaro can affect eyesight. The clinically useful answer is that vision symptoms need context.

There are three separate issues that patients often mix together: temporary blurred vision when blood glucose changes quickly, diabetic retinopathy worsening in some people with diabetes, and rare optic nerve events, especially NAION, now recognised as a very rare semaglutide safety issue by the European Medicines Agency.

Urgent rule: sudden vision loss, rapidly worsening eyesight, a new dark or blank area in vision, or severe one-sided visual change needs same-day urgent eye assessment or emergency care.

Sudden vision loss is urgent

If you have sudden vision loss, rapidly worsening eyesight, a new dark or blank area in your vision, or severe one-sided visual change, seek same-day urgent eye assessment or emergency care.

This is not a symptom to monitor for weeks or to save for a routine appointment.

For semaglutide medicines such as Ozempic and Wegovy, the EMA Pharmacovigilance Risk Assessment Committee concluded in June 2025 that non-arteritic anterior ischemic optic neuropathy, or NAION, is a very rare side effect. The EMA described the frequency as up to 1 in 10,000 people. If NAION is confirmed, the prescribing clinician would normally stop semaglutide in line with product guidance.

This does not mean most vision symptoms on GLP-1 treatment are NAION. It means sudden or rapidly worsening vision symptoms deserve urgent attention. Patients on semaglutide with these symptoms should contact a doctor or urgent eye service without delay and follow medical advice on whether treatment should be paused while being assessed.

What is NAION?

NAION is a condition where blood flow to the optic nerve is disrupted. It can cause sudden painless vision loss, usually in one eye. It is more common in people with vascular risk factors such as diabetes, high blood pressure, sleep apnoea, and crowded optic discs.

A 2024 retrospective matched cohort study by Hathaway and colleagues in JAMA Ophthalmology reported a higher NAION risk among semaglutide-prescribed patients compared with matched non-GLP-1 comparators. The study was important, but it was observational and from a neuro-ophthalmology setting, so it could not prove causality.

A 2025 Danish-Norwegian registry cohort by Pottegård and colleagues in Diabetes, Obesity and Metabolism also found an increased relative risk signal in people with type 2 diabetes, while the absolute risk difference remained small.

Later meta-analyses and consensus statements have not all weighed the evidence identically. The practical conclusion is cautious: semaglutide may increase relative risk of NAION, but the absolute risk appears low and causality is still being clarified.

Diabetic retinopathy is a different issue

Diabetic retinopathy is damage to the retina caused by diabetes. It is not the same as NAION.

The best-known signal comes from SUSTAIN-6, a randomised cardiovascular outcomes trial by Marso and colleagues in the New England Journal of Medicine in 2016. The trial included 3,297 patients with type 2 diabetes at high cardiovascular risk. Diabetic retinopathy complications were higher in the semaglutide group than the placebo group.

That sounds alarming if read alone. But later analysis matters.

A post-hoc analysis by Vilsbøll and colleagues in Diabetes, Obesity and Metabolism in 2018 found that the SUSTAIN-6 signal appeared largely linked to the size and speed of HbA1c reduction in the first 16 weeks, especially in patients with pre-existing diabetic retinopathy, poor baseline glucose control, and insulin use.

A 2021 meta-regression by Bethel and colleagues in Diabetes Care looked across six GLP-1 receptor agonist cardiovascular outcomes trials. Overall GLP-1 treatment was not significantly associated with retinopathy, but greater HbA1c reduction correlated with higher retinopathy risk.

So the practical message is not “GLP-1 medicines damage eyes.” A better message is: if a person with diabetes has existing retinopathy or very high glucose, rapid glucose improvement can temporarily worsen retinopathy in susceptible patients. That is a known phenomenon in diabetes care, not only with GLP-1 treatment.

Temporary blurred vision can happen when glucose changes

Some people with diabetes notice blurred vision when blood glucose changes quickly. This is mainly relevant to people with diabetes or large changes in blood glucose. It can happen because the lens of the eye changes shape as glucose and fluid balance shift.

Okamoto and colleagues studied refractive changes during intensive glucose control in diabetic patients in the British Journal of Ophthalmology in 2000. They found temporary hyperopic shifts after rapid glucose improvement, with recovery over days to weeks.

Sonmez and colleagues reported similar glucose-related refractive changes in Cornea in 2005. A 2018 systematic review by Wiemer and colleagues in Seminars in Ophthalmology also found that diabetes-related refractive shifts are associated with blood glucose variation.

This kind of blurred vision is not the same as optic nerve damage or diabetic retinopathy progression. Still, persistent, severe, one-sided, or sudden symptoms should be assessed.

What about Mounjaro?

Mounjaro contains tirzepatide, a dual GIP/GLP-1 receptor agonist. Current European product information for Mounjaro says it has not been studied in patients with certain advanced diabetic eye diseases, including proliferative diabetic retinopathy and diabetic macular oedema. It should be used with caution in these patients with appropriate monitoring.

That is not the same as proof that Mounjaro causes diabetic eye disease. It is a caution because high-risk patients were not adequately studied.

A 2025 observational study in Communications Medicine compared ocular outcomes for tirzepatide and other anti-obesity medicines in people with obesity, including matched comparisons against semaglutide. It did not show major differences in ocular outcomes between tirzepatide and semaglutide. This is reassuring, but observational studies cannot fully settle rare-event safety questions.

Who should be more careful?

Patients should tell their clinician before starting or escalating treatment if they have diabetes with known retinopathy, previous laser, injection, or surgery for diabetic eye disease, very high HbA1c, rapidly changing glucose, insulin use, previous optic nerve disease or NAION, sudden vision symptoms, sleep apnoea, high blood pressure, or other vascular risk factors.

For patients with diabetes, up-to-date retinal screening matters, especially before starting or escalating treatment if they have known retinopathy, high HbA1c, long diabetes duration, or insulin use. For patients without diabetes, diabetic retinopathy is not the main issue, but sudden vision loss still needs urgent evaluation.

How Élan handles this risk

Élan's approach is long-term weight maintenance, not maximum speed at any cost. For patients with diabetes or eye-risk history, safe treatment means asking about diabetic eye disease before treatment decisions, avoiding false reassurance when symptoms are sudden or severe, encouraging eye screening when diabetes risk makes it relevant, adjusting the plan to the patient's risk profile, and protecting nutrition, muscle, and long-term maintenance while weight changes.

The goal is not to frighten patients away from effective treatment. The goal is to make sure the right patient gets the right monitoring.

Bottom line

Vision symptoms during GLP-1 based treatment need context. For diabetes patients, blurred vision may come from glucose changes, and retinopathy risk is mainly relevant when existing diabetic eye disease and rapid HbA1c improvement are present.

For semaglutide medicines, NAION is now recognised by EMA as a very rare safety issue. Sudden or rapidly worsening eyesight should be treated as urgent.

For Mounjaro, the main current caution is appropriate monitoring in patients with advanced diabetic eye disease, because these groups were not fully studied.

If you are using Ozempic, Wegovy, or Mounjaro and have vision concerns, diabetes, known retinopathy, or previous optic nerve disease, book a medical consultation with Élan Clinic to review your individual risk and monitoring plan.

Sources